Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener has recently sold shares of the company, according to the latest SEC filings. The transaction, which took place on May 2, 2024, involved the sale of 1,799 shares at an average price of $23.31, totaling over $41,934.
The shares were sold under a pre-arranged 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information. The sales occurred in multiple transactions at prices ranging from $23.05 to $23.46.
Following the sale, Vakiener still owns 30,205 shares in the company. The ownership includes common stock underlying restricted stock units that are subject to certain vesting conditions.
Investors often monitor insider sales as they can provide insights into an insider's view of the company's value. However, it's important to note that these transactions can be motivated by a variety of factors and may not necessarily reflect a negative outlook on the company's future performance.
Arrowhead Pharmaceuticals is a biopharmaceutical company engaged in the development of medicines for the treatment of intractable diseases. The company's stock performance and insider trading activities are closely watched by the market for indications of the company's health and future prospects.
InvestingPro Insights
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been subject to close scrutiny from investors, especially following recent insider trading activity. To provide a clearer picture of the company's financial health and future outlook, it's valuable to consider the latest data and insights from InvestingPro.
InvestingPro Data shows that Arrowhead Pharmaceuticals holds a market capitalization of $3.12 billion USD, which is significant for a company in the biopharmaceutical sector. Despite this, the company's revenue has seen a decline, with a -34.71% change in the last twelve months as of Q1 2024, and an even steeper quarterly revenue growth decline of -94.32% in Q1 2024.
Furthermore, the company's Price / Book ratio stands at a high 19.43 as of the last twelve months up to Q1 2024, which could be a point of concern for value-oriented investors. This high valuation metric is coupled with a negative P/E Ratio of -10.5, indicating that the market may be expecting future growth or the current earnings do not justify the stock price.
One of the InvestingPro Tips highlights that 5 analysts have revised their earnings estimates upwards for the upcoming period, suggesting that there may be some optimism regarding Arrowhead Pharmaceuticals' earnings potential. However, it's also noted that analysts anticipate a sales decline and a drop in net income for the current year, and they do not expect the company to be profitable this year.
Still, Arrowhead Pharmaceuticals is reported to have liquid assets that exceed its short-term obligations, which is a positive sign of the company's ability to meet its immediate financial liabilities. Additionally, the company operates with a moderate level of debt, which can be a balancing factor in financial stability.
For investors looking for more comprehensive analysis and additional insights, there are more InvestingPro Tips available at InvestingPro, including metrics on profitability, debt levels, and dividend policies. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. As of now, there are 9 additional InvestingPro Tips listed for Arrowhead Pharmaceuticals on InvestingPro, providing a more in-depth understanding of the company's financial situation and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.